Related Experiment Video
Updated: May 13, 2026
Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds
Published on: October 20, 2012
Effect of Continuous Intraoperative Dexmedetomidine on Interleukin-6 and Other Inflammatory Markers After Coronary
Ranko Zdravković1,2, Sanja Vicković1,3, Mihaela Preveden1,2
1Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
Insights
Continuous intraoperative dexmedetomidine did not reduce inflammatory markers like IL-6 after coronary artery bypass graft (CABG) surgery. The study found no significant difference in IL-6, CRP, WBC, or fibrinogen levels between groups receiving dexmedetomidine or saline.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Immunology
Background:
- Coronary artery bypass graft (CABG) surgery is a common procedure.
- Postoperative inflammatory response significantly contributes to complications and mortality after CABG.
- Interleukin-6 (IL-6) and C-reactive protein (CRP) are key inflammatory markers.
Purpose of the Study:
- To evaluate the efficacy of continuous intraoperative dexmedetomidine in mitigating the postoperative inflammatory response following CABG surgery.
- To assess the impact of dexmedetomidine on IL-6, CRP, white blood cells (WBC), and fibrinogen levels.
Main Methods:
- Prospective experimental study involving 100 patients undergoing CABG surgery.
- Experimental group (n=50) received continuous intraoperative dexmedetomidine (0.5 μg/kg/h).
- Control group (n=50) received an equivalent volume of saline.
- Primary outcomes measured were changes in IL-6, CRP, WBC, and fibrinogen from preoperative to postoperative day 1 (POD1).
Main Results:
- No significant difference was observed in the increase of IL-6 (ΔIL-6), CRP (ΔCRP), WBC (ΔWBC), or fibrinogen (Δfibrinogen) between the dexmedetomidine and saline groups.
- All measured inflammatory markers (IL-6, CRP, WBC, fibrinogen) showed a significant increase from preoperative levels to POD1 in both groups.
- Demographic data, including age and sex distribution, were comparable between the two groups.
Conclusions:
- Continuous intraoperative administration of dexmedetomidine at 0.5 μg/kg/h without a loading dose did not attenuate the postoperative inflammatory response after CABG surgery.
- The findings suggest that this dexmedetomidine regimen is not effective in reducing key inflammatory markers in the early postoperative period following CABG.
Abstract:
Background and Objectives: Coronary artery bypass graft (CABG) surgery is the most common cardiac surgery. One of the main causes of postoperative complications and increased mortality after CABG is the inflammatory response. The aim of this study was to investigate whether continuous intraoperative dexmedetomidine can reduce the increase of IL-6 and other inflammatory markers after CABG surgery. Materials and Methods: The study is registered with ClinicalTrials.gov, NCT06378827, accessed on 23 April 2024. This prospective experimental study was conducted from April to December 2024 and included 100 patients undergoing CABG surgery. Patients in the experimental group (50 patients) received a continuous infusion of dexmedetomidine (0.5 μg/kg/h) from anesthesia induction until the end of surgery, while the patients in the control group (50 patients) received the same volume of saline. The primary outcomes were the changes in the values of interleukin-6 (IL-6), C-reactive protein (CRP), white blood cells (WBC), and fibrinogen on the first postoperative day (POD1) compared to the basal, preoperative values. Results: The patients in the control group were on average 65.26 years old, and the patients in the experimental group were 66.28 years old (p = 0.555). From the control group, 40 (80%) patients were male compared to 37 (74%) patients from the experimental group (p = 0.635). Median IL-6 before surgery was 2.0 pg/mL, while on POD 1 it was 76.2 pg/mL (p < 0.001). Median CRP before surgery was 2.5 mg/dL, while the POD1 value was 45.5 mg/dL (p < 0.001). Median WBC values were 6.7 × 109/L before surgery and 13.6 × 109/L on POD1 (p < 0.001). The average value of fibrinogen was 3.19 g/L before surgery, while on POD1 it was 3.37 g/L (p = 0.024). The increase in IL-6 on POD1 (ΔIL-6) was 72.4 pg/mL in the control group and 73.0 pg/mL in the experimental group (p = 0.427). ΔCRP was 41.2 mg/mL (control group) and 38.0 mg/mL (experimental group) (p = 0.725). ΔWBC was 7.45 × 109/L (control group) and 6.81 × 109/L (experimental group) (p = 0.407). Δfibrinogen was 0.16 g/L (control group) and 0.2 g/L (experimental group) (p = 0.771). Conclusions: Intraoperative administration of dexmedetodine during CABG surgery at a dose of 0.5 µg/kg/h without a loading dose does not lead to a decrease in the intensity of the inflammatory response after surgery.
More Related Videos
Related Concept Videos
01:18Endocarditis III: Medical Management
01:23Peripheral Artery Disease V: Postoperative Nursing Management